To animate the Banner

Talent Recruitment

Sales Department

Apply for post

Recruitment Position

Place of work

Number of Recruits

Salary Treatment

Obitinib 6

Obitinib (trade name: Yinokai) is a highly selective new BTK inhibitor independently developed by Nuo Cheng Jianhua. As a new type of irreversible covalent binding BTK inhibitor, orbitinib has an innovative compound structure, which makes it highly selective, reduces off-target effects, and has better efficacy and safety. Obitinib has been approved in China in 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and will be included in the national health insurance in 2021. How much. The clinical study of orbitinib in relapsed/refractory CLL/SLL showed an Independent Review Committee (IRC)-assessed overall response rate (ORR) of 92.5 percent and complete response rate (CR) of 21.3 percent. Investigator-assessed ORR and CR were 93.8 and 26.3, respectively. Detailed data can be found in an article published in the American Journal of Hematology (American Journal Of Hematology). How much. CLL/SLL, one of the most common types of leukemia, is an indolent malignancy of B lymphocytes. Although CLL/SLL is an indolent tumor, some patients develop disease progression over time. Globally, there are 191000 new cases of CLL and 61000 deaths each year. Obitinib has been included in the 2021 Guidelines for Diagnosis and Treatment of Malignant Lymphoma of the Chinese Society of Clinical Oncology (CSCO), and has been listed as a first-class recommend plan for the treatment of relapsed/refractory chronic CLL/SLL, and has won a number of innovation awards, Including: the first prize of Beijing Invention Patent Award, Beijing New Technology and New Product (Service) Certificate, 2021 China International Service Trade Fair "Science and Technology Innovation Service Demonstration Case.

Job Application

Name

Gender

Male

Female

Ethnic

Age

E-mail

Marriage

Unmarried

Married

Weight

Height

Native Place

political outlook

Expected location

education level

Professional

foreign language level

graduation school

Graduation time

—

Other Intended Positions

Contact Phone

Resume Upload

Please upload a resume file smaller than 5M ~

Self-evaluation

Security Verification

Job Application

Focus on us

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Contact Information

020-32030745

Monday to Friday 9:00~17:00

Virotech@virot.cn

Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City

粤ICP备XXXXXXXX号

Tags | city substation | Business License | Powered by www.300.cn